ciprofloxacin has been researched along with ulifloxacin in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kazuno, K; Kise, M; Kitano, M; Matsuda, M; Matsuoka, M; Ozaki, M; Segawa, J; Shirahase, I; Tomii, Y | 1 |
| Biedenbach, DJ; Fritsche, TR; Jones, RN | 1 |
| Drlica, K; Hiasa, H; Kerns, RJ; Malik, M; Marks, KR; Mustaev, A | 1 |
| Kimura, K; Kise, M; Kitano, M; Matsuda, M; Nishino, T; Otsuki, M; Ozaki, M; Segawa, J; Shibata, K; Tomii, Y | 1 |
| Mitsuhashi, S; Yoshida, T | 1 |
| Honmura, T; Komori, K; Matsuda, M; Nishimura, I; Nishino, T; Ozaki, M; Tomii, Y; Yamaguchi, R | 1 |
| Araake, M; Hara, T; Nishino, T; Watabe, H | 1 |
| Araake, M; Hara, T; Nishino, T; Shimizu, M; Tabata, M; Watabe, H | 1 |
| Araake, M; Maebashi, K; Tani, M; Watabe, H | 1 |
| Keam, SJ; Perry, CM | 1 |
| Hikida, M; Kariyama, R; Kato, Y; Kumon, H; Mikuniya, T; Monden, K | 1 |
| Cagini, C; Pellegrino, RM; Segoloni, F | 1 |
| Di Maggio, T; Mantengoli, E; Montagnani, F; Pallecchi, L; Pollini, S; Riccobono, E; Rossolini, GM | 1 |
1 trial(s) available for ciprofloxacin and ulifloxacin
| Article | Year |
|---|---|
Prulifloxacin.
Topics: Administration, Oral; Amoxicillin; Animals; Anti-Bacterial Agents; Bronchitis, Chronic; Ciprofloxacin; Clavulanic Acid; Dioxolanes; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Half-Life; Humans; Italy; Molecular Structure; New Zealand; Pefloxacin; Piperazines; Prodrugs; Quinolones; Urinary Tract Infections | 2004 |
12 other study(ies) available for ciprofloxacin and ulifloxacin
| Article | Year |
|---|---|
Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Carboxylic Acids; Escherichia coli Infections; Fluoroquinolones; Male; Mice; Microbial Sensitivity Tests; Pseudomonas Infections; Quinolones; Structure-Activity Relationship | 1992 |
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
Topics: Anti-Bacterial Agents; Diarrhea; Dioxolanes; Fluoroquinolones; Gastroenteritis; Gram-Negative Bacteria; Humans; Piperazines; Population Surveillance; Prodrugs | 2009 |
Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones.
Topics: Anti-Infective Agents; Aza Compounds; DNA Gyrase; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Protein Binding; Quinolines; Topoisomerase II Inhibitors | 2011 |
In vivo evaluation of NM441, a new thiazeto-quinoline derivative.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dogs; Drug Evaluation, Preclinical; Enoxacin; Female; Fluoroquinolones; Male; Mice; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Prodrugs; Quinolones; Respiratory Tract Infections; Streptococcal Infections; Urinary Tract Infections | 1991 |
Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Dioxolanes; Enoxacin; Fluoroquinolones; Microbial Sensitivity Tests; Mutation; Naphthyridines; Ofloxacin; Piperazines; Quinolones; Topoisomerase II Inhibitors | 1993 |
Uptake and intracellular activity of NM394, a new quinolone, in human polymorphonuclear leukocytes.
Topics: Amino Acids; Anti-Infective Agents; Antimetabolites; Ciprofloxacin; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; In Vitro Techniques; Neutrophils; Nucleic Acids; Ofloxacin; Phagocytosis; Piperazines; Pseudomonas aeruginosa; Quinolones | 1996 |
[In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dosage Forms; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fleroxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Prodrugs; Quinolones | 2002 |
[In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Time Factors | 2002 |
[Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Topoisomerase II Inhibitors | 2002 |
Synergistic effect of fosfomycin and fluoroquinolones against Pseudomonas aeruginosa growing in a biofilm.
Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Drug Synergism; Fluoroquinolones; Fosfomycin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Pseudomonas aeruginosa; Quinolones | 2005 |
Simultaneous determination of Ciprofloxacin and the active metabolite of Prulifloxacin in aqueous human humor by high-performance liquid chromatography.
Topics: Aged; Aged, 80 and over; Aqueous Humor; Calibration; Chromatography, High Pressure Liquid; Ciprofloxacin; Dioxolanes; Female; Fluoroquinolones; Humans; Male; Middle Aged; Piperazines; Reproducibility of Results | 2008 |
Antipneumococcal activity of ulifloxacin compared to levofloxacin and ciprofloxacin.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Italy; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Pneumococcal Infections; Streptococcus pneumoniae | 2011 |